CTOs on the Move

BioVest International

www.biovest.com

 
BioVest International is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.biovest.com
  • 324 S Hyde Park Ave Ste 350
    Tampa, FL USA 33606
  • Phone: 813.864.2558

Executives

Name Title Contact Details

Similar Companies

Metrics

Metrics provides pharmaceutical product development including pre-formulation studies, formulation development, clinical trial batch manufacturing and clinical trial batch packaging and labeling for non-sterile dosage forms. In addition, Metrics

Daiichi Sankyo

Learn about who we are, our approach to scientific innovation, our areas of therapeutic focus, our products, commitments and more.

Processo Partners, In

Processo Partners, In is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Indegene

We are a technology-led healthcare solutions provider. We combine deep industry expertise with fit-for-purpose technology in an agile and scalable operating model. Many of the leading, global healthcare organizations rely on us to deliver effective and efficient clinical, medical, and commercial outcomes every day. From strategy to execution, we enable healthcare organizations be future ready.

XTuit

XTuit Pharmaceuticals, Inc. is a biopharmaceutical company developing novel microenvironment-activated therapeutics targeting key mechanisms resulting in hypoxia, decreased drug uptake, drug resistance, and decreased immune response. The Company’s proprietary drug development pipeline and integrated, sophisticated clinical biomarker platform will be used for accelerated clinical development across selected cancers and fibrotic disorders. XTuit’s compounds act through pleiotropic mechanisms to inhibit extracellular matrix synthesis and stabilization, and to silence activated stromal cells, including cancer-associated fibroblasts and stellate cells. As a result, XTuit compounds alleviate hypoxia and enable enhanced drug uptake through solid stress reduction. Moreover, the drugs have been shown to down-regulate stroma-induced tumor and inflammation signaling pathways to overcome treatment resistance. XTuit’s first two lead series are being developed for early clinical proof-of-concept in liver diseases and cancer.